Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISE-hATG: SAB-142 in Stage 3 Type 1 Diabetes
NCT07670650Phase 3Not yet recruiting
- Sponsor
- University of Florida
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 3 trial of SAB-142 in type 1 diabetes mellitus (T1D), sponsored by University of Florida. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SAB-142
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07670650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670650.